Topical TLR7 Agonist Imiquimod Can Induce Immune-Mediated Rejection of Skin Metastases in Patients with Breast CancerSylvia Adams, Sandra Demaria, Lina Kozhaya et al.|Clinical Cancer Research|2012Cited by 225
CT Scan Screening for Lung Cancer: Risk Factors for Nodules and Malignancy in a High-Risk Urban CohortAlissa Greenberg, William N. Rom, Feng Lü et al.|PLoS ONE|2012Cited by 40
Identification of an autoantibody panel to separate lung cancer from smokers and nonsmokersWilliam N. Rom, Eng M. Tan, Judith D. Goldberg et al.|BMC Cancer|2010Cited by 39
Long-term outcomes of pembrolizumab (pembro) in combination with gemcitabine (gem) and concurrent hypofractionated radiation therapy (RT) as bladder sparing treatment for muscle-invasive urothelial cancer of the bladder (MIUC): A multicenter phase 2 trial.Minas P. Economides, Scot A. Niglio, Ajjai Alva et al.|Journal of Clinical Oncology|2023Cited by 8
Data from Topical TLR7 Agonist Imiquimod Can Induce Immune-Mediated Rejection of Skin Metastases in Patients with Breast CancerSylvia Adams, Sandra Demaria, Lina Kozhaya et al.|Unknown|2023Cited by 0